SBI Life Insurance Company announced Q2FY26 results Net premium: Rs 24,84,831 lakh compared to Rs 20,26,610 lakh during Q2FY25. PBT: Rs 51,318 lakh compared to Rs 54,693 lakh during Q2FY25. PAT: Rs 49,459 lakh compared to Rs 52,942 lakh during Q2FY25. Private Market leadership in Individual New Business Premium and Individual Rated Premium with market share of 25.4% & 22.6% respectively. Annualized Premium Equivalent (APE) stands at Rs 99.2 billion with growth of 10%. Total New Business Sum Assured stands at Rs 7,117.4 billion with 99% growth. Improvement in 13M persistency by 70 bps. Value of New Business (VoNB) stands at Rs 27.5 billion with growth of 14%. VoNB Margin stands at 27.8%. Indian Embedded value (IEV) stands at Rs 760 billion with growth of 15%. Robust Solvency ratio of 1.94. Assets under Management stands at Rs 4.8 trillion with 10% growth. Operating Return on Embedded Value stands at 17.6% Amit Jhingran, MD & CEO, SBI Life, said: "We welcome the Indian Government’s GST reforms, a key step toward insurance coverage for all by 2047, improving affordability and accessibility. These reforms will drive broader adoption, financial security and sustainable sector growth. Q2FY26 saw growth along with strategic product mix shifts and strong performance in Individual and group protection segments. Individual New Business Premiums gained momentum, shifting towards guaranteed nonpar savings and protection solutions. 13th month persistency improved, reflecting strong customer relationships. Distribution channels including agency, bancassurance, brokers and digital platforms expanded market reach. We remain committed to customer trust, product innovation and disciplined execution for sustained growth and long-term value creation." Result PDF
Pharmaceuticals company Dr. Reddy's Laboratories announced Q2FY26 results Revenue: Rs 88,051 million, change 9.8% YoY; 3% QoQ. EBITDA: Rs 23,511 million for Q2FY26. EBITDA Margin: 26.7% for Q2FY26. PBT: Rs 18,350 million, change -4% YoY; -4% QoQ. PAT: Rs 14,372 million, change 14% YoY; 1% QoQ. G V Prasad, Co-Chairman & MD, said: "Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRT) portfolio, which helped offset the decline in U.S. Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and Pursuing business development initiatives." Result PDF
IT Consulting & Software company Coforge announced Q2FY26 results Revenue: Rs 3,986 crore / USD 462 million. Up 8.1% QoQ in Rs terms, 5.9% in CC terms, 4.5% in USD terms. Up 31.7% YoY in Rs terms, 25.7% in CC terms, 26.6% in USD terms. EBIT margin at 14%, up 251 bps QoQ and 240 bps YoY. EBITDA: USD 84 million, up 11.5% QoQ and 42% YoY in USD terms. EBITDA margin at 18.3%, up 115 bps QoQ and 199 bps YoY. PAT: Rs 376 crores, up 18.4% on a QoQ basis and 86.0% on a YoY basis. The Board has recommended an interim dividend of Rs 4/- per share, and the record date for this payout will be October 31, 2025. Sudhir Singh, Chief Executive Officer & Executive Director, Coforge, said: “The 8.1% sequential Rs growth in Q2, a next twelve-month signed order book which is 26.7% higher YoY, a sales execution engine that signed 14 large deals last year and has already closed 10 large deals in the first half of this year, an EBIT margin expansion of 250 bps QoQ, coupled with one of the lowest employee attrition rates across the industry are all pointers to what we believe will be an exceptional fiscal’26. We remain steadfast in our commitment to turning in the ninth consecutive year of sustained and robust growth despite the uncertain macros.” Result PDF